Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Patients with well-compensated NASH cirrhosis and three metabolic risk factors were selected for inclusion in the study.

The London-based biotechnology company said the non-dilutive funding will support its ongoing development of its lead gene therapy, GF-1002, for the treatment of metabolic associated steatohepatitis, ...

Last week, BioVie announced a significant milestone: a Notice of Allowance from the Japan Patent Office for its application regarding a novel liquid formulation of terlipressin. This formulation, ...

Liver fibrosis causes scar tissue to form on the liver, sometimes leading to chronic liver disease. Learn about noninvasive ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg ...

Ultra-processed food consumption in obese adolescents is linked to insulin resistance and liver disease, stressing the need ...

Madrigal Pharmaceuticals (MDGL) announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated ...

An FDA AdCom in September recommended against full approval for Ocaliva by a 13-1 vote for the treatment of primary biliary ...